Colchicine is an anti-inflammatory drug that works by disrupting a key structural component inside your cells. It’s used primarily to treat gout flares, pericarditis, and familial Mediterranean fever, and was approved by the FDA more recently to reduce cardiovascular risk in people with established heart disease. Its usefulness across such different conditions comes down to one shared mechanism: it dials down inflammation at the cellular level.
How Colchicine Works Inside Your Cells
Every cell in your body contains tiny tube-shaped structures called microtubules. These tubes act like scaffolding, helping cells keep their shape, divide, and move. Colchicine binds to the protein building blocks of these tubes (called tubulin) and prevents them from assembling properly. When colchicine attaches, it forces a shape change in the protein that blocks the normal connections needed for the tubes to form. Depending on the dose, this can slow assembly or destroy existing tubes altogether.
This matters most for immune cells called neutrophils, which are the first responders to inflammation. Neutrophils rely on their internal scaffolding to migrate toward an inflamed area, release inflammatory signals, and engulf debris like uric acid crystals. By disrupting that scaffolding, colchicine effectively slows the inflammatory cascade before it spirals. That’s why it works so well for conditions driven by bursts of intense inflammation rather than chronic immune dysfunction.
Gout: The Most Common Use
Colchicine has been used for gout for centuries. During an acute gout flare, uric acid crystals in a joint trigger a massive neutrophil response, which is what causes the sudden, severe pain and swelling. Colchicine interrupts that response. For an acute flare, the standard approach is 1.2 mg taken at the first sign of symptoms, followed by 0.6 mg one hour later, for a maximum of 1.8 mg in that first hour. Older dosing regimens used much higher amounts, but this lower-dose protocol has been shown to be equally effective with far fewer side effects.
Beyond treating active flares, colchicine is also used as a preventive measure. When someone starts a urate-lowering therapy (a long-term medication to reduce uric acid levels), the body’s adjustment period can paradoxically trigger more flares. A daily low dose of 0.5 mg during this transition helps keep those flares at bay. Evidence over the past decade supports this low-dose strategy for both gout prevention and broader cardiovascular benefit.
Heart Disease and Pericarditis
Colchicine’s role in heart health has grown significantly. Inflammation plays a major part in the progression of atherosclerosis, the buildup of plaque in arteries. The LoDoCo2 trial found that adding low-dose colchicine to standard care in patients with established cardiovascular disease reduced the combined risk of heart attack, stroke, coronary procedures, and cardiovascular death by 31% compared to placebo. Based on this evidence, the FDA approved colchicine specifically for reducing cardiovascular risk.
For pericarditis, an inflammation of the sac surrounding the heart, colchicine is a cornerstone of treatment. Recurrent pericarditis is notoriously difficult to manage, and a meta-analysis in the Journal of the American Heart Association found that colchicine cut the risk of recurrence by 54% compared to standard therapy alone. It’s typically used alongside a conventional anti-inflammatory for the initial episode and is especially valuable for preventing the frustrating cycle of repeated flares.
Familial Mediterranean Fever
Familial Mediterranean fever (FMF) is a genetic condition that causes recurring episodes of fever, chest pain, and abdominal pain driven by uncontrolled inflammation. The most serious long-term risk is amyloidosis, a condition where abnormal protein deposits accumulate in organs, particularly the kidneys. A landmark study published in the New England Journal of Medicine tracked over 1,000 FMF patients for up to 11 years and found striking results: among those who took colchicine consistently, only 1.7% developed kidney-damaging protein in their urine after 11 years. Among those who didn’t take it reliably, that number was 48.9%. Colchicine is considered lifelong therapy for FMF and remains the primary way to prevent organ damage.
Common Side Effects
Gastrointestinal problems are the most frequent side effect. A systematic review of randomized trials found that about 18% of people taking colchicine experienced diarrhea, compared to 13% in placebo groups. Overall gastrointestinal symptoms (including nausea, vomiting, abdominal pain, and bloating) occurred at a similar rate of roughly 18%. The good news is that colchicine does not appear to increase rates of liver problems, muscle damage, infections, or blood cell abnormalities at standard therapeutic doses.
Diarrhea is often the first warning sign that you’re at the upper edge of what your body can tolerate. If it develops, reducing the dose usually resolves it. This side effect profile is one reason the older high-dose gout regimens have been largely abandoned in favor of lower doses.
Narrow Therapeutic Window
Colchicine has a narrow gap between an effective dose and a toxic one. The effective concentration in the blood and the level where toxicity begins are close together, which is why precise dosing matters more with this drug than with many others. Colchicine poisoning, while rare at prescribed doses, unfolds in phases: gastrointestinal symptoms within the first 24 hours, followed by potential organ damage over the next several days. Severe cases can involve heart failure, blood clotting problems, and dangerously low blood pressure.
People with reduced kidney or liver function are at higher risk because their bodies clear the drug more slowly, allowing it to accumulate. No dose adjustment is needed for mild kidney impairment. For moderate impairment, doses are typically cut, and for severe impairment, further reductions are necessary. The American College of Rheumatology recommends dose adjustments at the clinician’s discretion, and some guidelines suggest halving the dose when kidney filtration drops below a certain threshold.
Drug Interactions to Know About
Colchicine is broken down and transported out of cells through two pathways that many other common drugs also use. When another medication blocks those pathways, colchicine levels in the blood can rise dramatically.
The most dangerous interaction is with clarithromycin, a widely prescribed antibiotic. Clarithromycin blocks both clearance pathways simultaneously and can increase colchicine exposure by roughly 280%. Fatalities have been reported from this combination, and expert guidelines classify it as a pairing that should be avoided entirely. Certain statins, particularly atorvastatin and simvastatin, also interact with colchicine. Both drugs can cause muscle damage on their own, and combining them raises that risk. Numerous case reports document muscle pain and weakness (myopathy) in patients taking both, especially those with kidney problems or other predisposing factors. Cyclosporine, an immunosuppressant, carries a similar risk.
If you take colchicine regularly, any new prescription warrants a check for interactions. This is especially important for antibiotics, cholesterol medications, and antifungal drugs, all of which commonly overlap with colchicine’s clearance pathways.